These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 19199893

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X, Girach A, Jimenez MC, Vignati L, PKC-DRS2 Study Group.
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The potential role of PKC beta in diabetic retinopathy and macular edema.
    Aiello LP.
    Surv Ophthalmol; 2002 Dec; 47 Suppl 2():S263-9. PubMed ID: 12507628
    [Abstract] [Full Text] [Related]

  • 6. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
    Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, Shahri N, Berg PH, MBDL and MBCU Study Groups.
    Invest Ophthalmol Vis Sci; 2013 Mar 11; 54(3):1750-7. PubMed ID: 23404115
    [Abstract] [Full Text] [Related]

  • 7. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
    Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC, PKC-DRS and PKC-DRS2 Study Groups.
    Retina; 2011 Nov 11; 31(10):2084-94. PubMed ID: 21862954
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors.
    Frank RN.
    Am J Ophthalmol; 2002 May 11; 133(5):693-8. PubMed ID: 11992868
    [Abstract] [Full Text] [Related]

  • 10. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
    PKC-DRS Study Group.
    Diabetes; 2005 Jul 11; 54(7):2188-97. PubMed ID: 15983221
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ruboxistaurin for diabetic retinopathy.
    Gardner TW, Antonetti DA.
    Ophthalmology; 2006 Dec 11; 113(12):2135-6. PubMed ID: 17157131
    [No Abstract] [Full Text] [Related]

  • 13. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.
    PKC-DMES Study Group.
    Arch Ophthalmol; 2007 Mar 11; 125(3):318-24. PubMed ID: 17353401
    [Abstract] [Full Text] [Related]

  • 14. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.
    Strøm C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M.
    Invest Ophthalmol Vis Sci; 2005 Oct 11; 46(10):3855-8. PubMed ID: 16186374
    [Abstract] [Full Text] [Related]

  • 15. Protein kinase C inhibitors in the treatment of diabetic retinopathy. Review.
    Gálvez MI.
    Curr Pharm Biotechnol; 2011 Mar 01; 12(3):386-91. PubMed ID: 20939796
    [Abstract] [Full Text] [Related]

  • 16. Diabetic macular oedema and visual loss: relationship to location, severity and duration.
    Gardner TW, Larsen M, Girach A, Zhi X, Protein Kinase C Diabetic Retinopathy Study (PKC-DRS2) Study Group.
    Acta Ophthalmol; 2009 Nov 01; 87(7):709-13. PubMed ID: 19817721
    [Abstract] [Full Text] [Related]

  • 17. Ruboxistaurin: LY 333531.
    Drugs R D; 2007 Nov 01; 8(3):193-9. PubMed ID: 17472415
    [Abstract] [Full Text] [Related]

  • 18. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
    Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP, Mbdv Study Group.
    Retina; 2011 Jun 01; 31(6):1053-9. PubMed ID: 21386766
    [Abstract] [Full Text] [Related]

  • 19. Ruboxistaurin mesilate hydrate for diabetic retinopathy.
    Schwartz SG, Flynn HW, Aiello LP.
    Drugs Today (Barc); 2009 Apr 01; 45(4):269-74. PubMed ID: 19499092
    [Abstract] [Full Text] [Related]

  • 20. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research.
    Donnelly R, Idris I, Forrester JV.
    Br J Ophthalmol; 2004 Jan 01; 88(1):145-51. PubMed ID: 14693793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.